Wolverine Trading, LLC Immunovant, Inc. Call Options Transaction History

Wolverine Trading, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$27.51 - $27.51 $60,522 - $60,522	2,200 Added 10.14%	23,900 $657,000
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $368,970 - $464,667	14,700 Added 210.0%	21,700 $572,000
Q1 2024 May 15, 2024	BUY	$30.27 - $43.79 $211,890 - $306,530	7,000 New	7,000 $226,000
Q3 2023 Nov 15, 2023	BUY	$18.55 - $39.96 $860,720 - $1.85 Million	46,400 New	46,400 $1.78 Million
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $62,094 - $100,646	-15,800 Reduced 26.78%	43,200 $232,000
Q2 2022 Aug 15, 2022	BUY	$3.38 - $5.65 $3,042 - $5,085	900 Added 1.55%	59,000 $240,000
Q1 2022 May 16, 2022	BUY	$5.06 - $8.77 $11,638 - $20,171	2,300 Added 4.12%	58,100 $320,000
Q4 2021 Feb 14, 2022	SELL	$7.33 - $9.32 $47,645 - $60,580	-6,500 Reduced 10.43%	55,800 $466,000
Q3 2021 Nov 12, 2021	SELL	$7.01 - $11.37 $275,493 - $446,840	-39,300 Reduced 38.68%	62,300 $549,000
Q2 2021 Aug 06, 2021	BUY	$9.4 - $16.85 $572,460 - $1.03 Million	60,900 Added 149.63%	101,600 $1.1 Million
Q1 2021 May 14, 2021	BUY	$13.08 - $49.6 $532,356 - $2.02 Million	40,700 New	40,700 $611,000

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.